Loading candles…
Nectar Lifesciences Ltd, incorporated in 1995, operates in the pharmaceutical industry with a focus on manufacturing and supplying Cephalosporin Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDF). The company serves global markets, including both regulated and semi-regulated regions. It is recognized as a significant player in the 3rd and 4th generation cephalosporins segment. Its primary business segments include Cephalosporin APIs and Finished Dosage Formulations, providing these products to international customers. There is no available information on founders, key management, subsidiaries, or stock exchange listings.
| To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 14 Aug 2025 |
| Other | To consider and approve, inter alia amongst other items, the mode of rewarding of shareholders as contemplated in the explanatory statement to item no. 3 of … | 23 Jul 2025 |
| Audited Results - FY25 | To consider and approve the Yearly Audited Financial results of the Company for the period ended March 2025 and Other business. | 7 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and other business matters | 30 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.